188 results on '"Stasik, Sebastian"'
Search Results
2. Prognostic impact of CEBPA mutational subgroups in adult AML
3. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
4. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
5. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome
6. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
7. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
8. Retained functional normal and preleukemic HSCs at diagnosis are associated with good prognosis in DNMT3AmutNPM1mut AMLs
9. Overlapping features of therapy-related and de novo NPM1-mutated AML
10. Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML
11. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
12. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
13. Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment
14. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
15. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
16. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
17. Exome sequencing identifies frequent genomic loss of TET1 in IDH-wild-type glioblastoma
18. Microbial Communities in Oil Sands Tailings: Their Implications in Biogeochemical Processes and Tailings Management
19. Mimicking Clinical Trials with Synthetic Acute Myeloid Leukemia Patients Using Generative Artificial Intelligence
20. Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents
21. PB1759: RETAINED FUNCTIONAL NORMAL AND/OR PRE-LEUKEMIC HSCS IN THE BONE MARROW ARE ASSOCIATED TO GOOD PROGNOSIS IN DNMT3AMUTNPM1MUT AML PATIENTS
22. S138: VALIDATION OF THE REVISED 2022 EUROPEAN LEUKEMIANET (ELN) RISK STRATIFICATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
23. Profiling of aberrant DNA methylation in acute myeloid leukemia reveals subclasses of CG-rich regions with epigenetic or genetic association
24. Response to (K)RASG12C and EGFR Inhibition in a Patient With NRASG12C-Mutated Rectal Cancer
25. Prognostic impact of CEBPAmutational subgroups in adult AML
26. Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy
27. Vertical gradients in carbon flow and methane production in a sulfate-rich oil sands tailings pond
28. Supplementary Table 1 from TERT Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with IDH Wild-Type Glioblastomas: A Pilot Prospective Study
29. Microbial Communities in Oil Sands Tailings: Their Implications in Biogeochemical Processes and Tailings Management
30. Mutated IKZF1is an independent marker of adverse risk in acute myeloid leukemia
31. UBTF tandem Duplications Account for a Third of Advanced Pediatric MDS without Genetic Predisposition to Myeloid Neoplasia
32. Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome
33. Understanding biogeochemical gradients of sulfur, iron and carbon in an oil sands tailings pond
34. Response to (K)RAS G12C and EGFR Inhibition in a Patient With NRAS G12C -Mutated Rectal Cancer.
35. Genomische Charakterisierung der IDH-Wildtyp Glioblastome in verschiedenen Altersgruppen
36. Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning
37. Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD
38. Additional file 1 of Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
39. Additional file 1 of Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
40. Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AML
41. Sensitive Quantification of Cell-Free Tumor DNA for Early Detection of Recurrence in Colorectal Cancer
42. High Potential for Anaerobic Microbial Sulfur Oxidation in Oil Sands Tailings Ponds
43. Prediction of Complete Remission and Survival in Acute Myeloid Leukemia Using Supervised Machine Learning
44. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European leukemia net risk classification
45. Loss-of-function mutations of bcor are an independent marker of adverse outcomes in intensively treated patients with acute myeloid leukemia
46. Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia
47. Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial
48. Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer
49. Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents
50. INNV-04. IDH MUTATION PREDICTION IN GLIOMA: A MULTIMODAL APPROACH
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.